TP53 and cancer: Previously, the activation of components of the immune system was demonstrated in the Pan02 murine subcutaneous pancreatic cancer model (which carries no KRAS or P53 mutations) using flow cytometry and bulk RNA sequencing (Qiagen “Cancer Inflammation and Immunity Crosstalk” SuperArray platform).